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Measurements of antigen-speciﬁc T cell responses in chronic diseases are limited by low frequencies of antigen-speciﬁc cells
in the peripheral blood. Therefore, attempts have been made to add costimulatory molecules such as anti-CD28 or IL-7/IL-
15 to ELISPOT assays to increase sensitivity. While this approach has been successful under certain circumstances, results are
often inconsistent. To date, there are no comprehensive studies directly comparing the in vitro eﬀects of multiple costimulatory
molecules in diﬀerent disease settings. Therefore, in the present study we tested the eﬀects of IL-7/IL-15, IFN-α, anti-ICOS, and
anti-CD28 on antigen-speciﬁc T cell responses in patients infected with HCV or HIV versus healthy individuals. Our data show
thatnoneoftheaforementionedmoleculescouldsigniﬁcantlyincreaseELISPOTsensitivity,neitherinHCVnorinHIV.Moreover,
all of them caused false-positive responses to HCV and HIV antigens in healthy individuals. Our results question the broad use of
in vitro costimulation.
Copyright © 2008 Stefanie Kuerten et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The measurement of immune responses to disease-speciﬁc
antigens has become increasingly important in chronic viral
infections. Particularly T cell responses have proven to be
a valuable tool both for vaccine development and immune
monitoring [1, 2]. Examining the phenotype and activation
status of T cells (e.g., by FACS analysis) or their cytokine
secretion proﬁle (e.g., in ELISPOT assays) not only provides
helpful information on the immunogenicity of individual
viral antigens, but also reﬂects the patient’s current state
of immunocompetence, a vital piece of information for
treatment and prognosis.
One major obstacle, however, is the intrinsically low-
frequency and cytokine productivity of T cells in hosts
suﬀering from chronic disease. Not only infections like
HIV that directly impair T cell function, but also viral
infections that target cells outside the immune system, such
as HCV, have been shown to decrease T cell reactivity to
viral antigensin vitro [3–10]. As shown by Yonkers et al.,
this eﬀect is even more pronounced in cases of HIV/HCV
coinfection [11]. This alteration of T cell function by chronic
viral infections makes it almost impossible to accurately
quantify the disease-speciﬁc T cell repertoire in vitro.
A great deal of hope has therefore been placed into
the use of in vitro costimulation. Adding molecules such
as agonistic anti-CD28 antibodies or cytokines like IL-7
and IL-15 to FACS and ELISPOT assays is intended to
optimize the interaction between T cells and APC [11–13].
The rationale of a strong second signal compensating for a
weak ﬁrst signal and/or a high T cell activation threshold is
indeed appealing. Pathogen-speciﬁc T cells would no longer
escape detection due to suboptimal in vitro stimulation, but
would be reliably activated above threshold and thus become
detectable. Following this rationale, in vitro stimulation
would allow for a precise quantiﬁcation of each individual’s
antigen-speciﬁc T cell repertoire.
Several studies have indeed shown increased T cell
responses after in vitro costimulation; Jennes et al. demon-
strated that the presence of IL-7 and IL-15 during T cell
stimulation in ELISPOT assays signiﬁcantly increases the
frequency of PPD-speciﬁc and CMV-speciﬁc T cells [12].2 Clinical and Developmental Immunology
Calarota et al. later demonstrated that IL-15 alone suﬃces to
enhance IFN-γ production to both simian-human immun-
odeﬁciency virus and HIV antigens in infected macaques
[14]. Finally, Ott et al. demonstrated that agonistic anti-
CD28 antibody increases the IFN-γ response to tetanus
toxoid, mumps antigen, CMV, and EBV peptides in healthy
individuals as well as responses to NS3 protein in HCV
patients and proinsulin along with islet cell antigen in type
1 diabetes patients [13].
Other studies, however, indicate a rather limited eﬀect
of in vitro costimulation. As Yonkers et al. demonstrated,
memory-eﬀector CD8 cells show reduced responsiveness
to CD28 costimulation in HCV/HIV coinfection [11].
Subudhi et al. carefully delineated the opposing eﬀects of B7
family members on immune responses, and showed that
immune modulators frequently lead to coinhibition rather
than the desired stimulation [15].
Much uncertainty therefore remains mainly because no
human study to date has systematically compared multiple
types of in vitro costimulation in the setting of diﬀerent
viral infections. Moreover, most studies compare stimulated
versusunstimulatedresponseswithininfectedpatients.Little
attention, however, has so far been paid to the eﬀect of in
vitro costimulation in healthy, uninfected individuals. How
speciﬁc are the responses obtained after costimulation? Is
the desired increase in assay sensitivity compromised by
decreased speciﬁcity?
Our present study sheds some light upon these essential
questions.Wesystematicallycomparedtheeﬀectsoffourdif-
ferent methods of in vitro costimulation: IL-7/IL-15,IFN-α,
anti-ICOS, and anti-CD28. Using IFN-γ ELISPOT assays
with and without costimulation, we measured the T cell
response to disease-speciﬁc antigens in 10 HCV patients, 10
HIV patients, and 6 healthy individuals. Our results lead to
three major conclusions. Firstly, in HCV patients, signiﬁcant
increases in T cell reactivity could only be seen with one
particular antigen (NS3 protein) when using either IL-7/IL-
15 or anti-CD28. Secondly, in HIV patients, none of the four
types of in vitro costimulation led to a statistically signiﬁcant
response increase, regardless of the antigen used. Lastly and
most importantly, all four methods of costimulation led to
false-positive responses to HCV and HIV antigens in healthy
individuals.
2. MATERIALS AND METHODS
2.1. Subjectsandsamplecollection
Peripheral blood was obtained from 10 HIV positive and
10 HCV-infected subjects—the former from the Special
Immunology Unit at University Hospitals of Cleveland, and
the latter from the Cleveland Veterans Aﬀairs Medical Center
and University Hospitals of Cleveland. HIV infection was
deﬁned as a positive result for ELISA or other licensed
HIV antibody tests, as well as previously detectable plasma
HIV RNA. HCV infection was deﬁned as detectable serum
HCV antibodies and RNA. The six healthy controls tested
were members of our and adjoining laboratories, and were
negative for both HIV and HCV antibodies. For all partici-
pants, PBMCs were isolated from 40–100mL of heparinized
blood by standard Ficoll density-gradient centrifugation
(IsoPrep, Robbins Scientiﬁc Corp., Sunnyvale, Calif, USA)
and immediately used for ELISPOT analysis. All studies were
performed under the approval of the Institutional Review
BoardforHumanInvestigationattheUniversityHospitalsof
ClevelandandtheClevelandVeteransAﬀairsMedicalCenter.
2.2. ELISPOTassaysandimageanalysis
ImmunoSpot plates (Cellular Technology Ltd., Cleveland,
Ohio, USA) were coated with IFN-γ capture antibody mAb
M700A (Endogen, Woburn, Mass, USA) in PBS (3μg/mL)
and placed at 4◦C overnight. The plates were then blocked
with PBS containing 1% BSA (Sigma-Aldrich, St. Louis, Mo,
USA) for 1 hour and washed three times with PBS. Freshly
isolated PBMCs were plated in RPMI-1640 (BioWhittaker,
Walkersville,Md, USA) supplemented with 100U/mL peni-
cillin, 100μg/mL streptomycin, 2mM L-glutamine, and 10%
pooled heat-inactivated human AB serum. For all experi-
ments, 3×105 PBMCswereplated perwellin thepresenceor
absence of IL-7/IL-15 (ﬁnal concentration of 5ng/mL; Cell
Sciences, Canton, Mass, USA), IFN-α (ﬁnal concentration
of 1000U/mL; Biosource, Camarillo, Calif, USA), agonistic
anti-ICOS antibody (ﬁnal concentration of 1μg/mL; eBio-
science, San Diego, Calif, USA), or agonistic anti-CD28
antibody (ﬁnal concentration of 1μg/mL; BD Pharmingen,
San Jose, Calif, USA). The following HIV antigen pools
were used: Pool 1 (comprised of HIV-1 peptides A0301 pol,
A201 pol 2, A24 nef8, and A201 nef1), Pool 2 (comprised
of HIV-1 peptides A24 gp41, B27 gp120, A301 p17, and
A201 nef2), and Pool 3 (comprised of HIV-1 peptides B27
gp41, A201 nef3, B51 nef, and A24 gp120). All peptide pools
were used at 10μg/mL. All HIV peptides were obtained from
the NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH. Recombinant HCV core
NS3 protein was supplied by Chiron (Emeryville, Calif,
USA) and used at a concentration of 10μg/mL. A set
of 73 MHC class I-restricted HCV peptides representing
portions of the HCV genotype 1 protein sequence, based
upon previously described CD8 determinants [16–19], were
synthesized by the multipin technique (Chiron, Emeryville,
Calif, USA.) and pooled together as a set (Pepset 4, used
at 3.4μM). Phytohemagglutinin (PHA) was used as positive
control in all assays, and was obtained from Sigma-Aldrich
(10μg/mL). Negative control wells contained PBMC with
a medium in the presence or absence of the costimulatory
agents as mentioned above. After 24 hours of incubation at
37◦C and 7% CO2, the plates were washed with PBS and
PBS/TWEEN, and IFN-γ biotinylated detection antibody
mAB M701 (Endogen, 2μg/mL) was added. The antibody
was diluted in PBS containing 1% BSA and 0.025% TWEEN
(Fisher Scientiﬁc International Inc., Hampton, NH, USA).
T h ep l a t e sw e r ei n c u b a t e da t4 ◦C overnight. Then they
were washed three times with PBS/TWEEN, and subse-
quently streptavidin-HRP conjugate (DAKO, Carpinteria,
Calif, USA) was added at 1/2000 dilution, incubated for
2 hours at room temperature, and removed by washing
twice with PBS and PBS/TWEEN. The spots were visualizedStefanie Kuerten et al. 3
Table 1: Clinical characteristics of study subjects. Data are given as means ± SD, unless otherwise speciﬁed. HCV: hepatitis C virus; HIV:
human immunodeﬁciency virus; ALT: alanine aminotransferase; N/A: not applicable.
HCV HIV Healthy
Gender n = 10 males n = 4 males n = 4 males
n = 6 females n = 2 females
Age 52.75 ±2.33 4 .8 ±5.92 9 .6 ±3.4
CD4 cell count, 106 cells/L N/A 451.3 ±134.9N / A
Plasma HIV RNA level, IU/mL 0.0 ±0.0 8,685.1 ±15,122.80 .0 ±0.0
HCV genotype Type 1: n = 9 N/A N/A
Type 2: n = 1
Plasma HCV RNA level, IU/mL 1,699,275 ±1,505,121 0.0 ±0.00 .0 ±0.0
Albumin, g/dL 3.9 ±0.5N / A N / A
ALT, IU/L 80.3 ±67.2N / A N / A
Total bilirubin level, mg/dL 0.5 ±0.3N / A N / A
Platelet count, 103 cells/mm3 211.6 ±55.8N / A N / A
On treatment 4/10 8/10 0/10
by adding HRP substrate 3-amino-9-ethylcarbozole (Pierce,
Rockford, Ill, USA). The reaction was stopped by rinsing the
plate with distilled water when distinct spots were visible
macroscopically. Plates were dried overnight and images of
t h eE L I S P O Tw e l l sw e r ec a p t u r e dw i t ha nI m m u n o S p o t
Series 5 Analyzer (Cellular Technology Ltd.). Image analysis
oftheELISPOTresultswasperformedwiththeImmunoSpot
5 Analysis Software (Cellular Technology Ltd.).
2.3. Statisticalanalysis
Mann-WhitneyranksumtestwascalculatedusingSigmaStat
(Version 7; SPSS Inc., San Jose, Calif, USA) to test for
signiﬁcant diﬀerences between values obtained with and
without the addition of IL-7/IL-15, IFN-α, anti-ICOS, or
anti-CD28, respectively. A probability value of P ≤ .05 was
considered to be statistically signiﬁcant.
3. RESULTS
3.1. Characteristicsofthestudysubjects
The clinical characteristics of the subjects evaluated for
HCV- and HIV-speciﬁc T cell functions as well as of healthy
individuals are listed in Table 1. Age and gender are listed
for all subjects. For HCV-infected patients, HCV genotype,
plasma HCV RNA levels, and platelet counts are given. Liver
function is represented by serum albumin levels, ALT levels,
andtotalbilirubinlevels.ForHIV-infectedpatients,CD4cell
counts and plasma HIV RNA levels are listed. The ratio of
treated to untreated patients is given for both patient groups.
3.2. IncreasedresponsestoNS3proteinin
HCV-infectedpatientsonlyafterinvitro
costimulationwithIL-7/IL-15oranti-CD28
I no r d e rt oc o m p a r et h ee ﬀects of diﬀerent types of in vitro
costimulation in 10 HCV-infected patients, we tested recall
responses to NS3 protein and Pepset 4 peptide pool in IFN-γ
ELISPOT assays. Results are shown in Figure 1.
Figure 1(a) illustrates the low baseline responses to
NS3 protein and Pepset 4 pool (2.5 ± 2.5a n d6 .8 ± 9.3
spots above medium, resp.) as frequently described in the
literature in the case of chronic infection [3–10]. The
presence of IL-7/IL-15 during in vitro T cell stimulation
led to a signiﬁcant ten-fold upregulation of IFN-γ recall
responses to NS3 protein (Figure 1(b); P = .02). Three of
the patients also showed increased responses to Pepset 4.
However, due to the wide range of spot numbers, the
mean increase was not statistically signiﬁcant. Neither IFN-α
(Figure 1(c))n o ra n t i - I C O S( Figure 1(d))h a dag e n e r a l
eﬀectonHCV-speciﬁcresponses.OnlyHCVpatients1and7
showed an increased NS3 response upon IFN-α stimulation
(P = .002 and P = .026, resp.). Costimulation with anti-
CD28 (Figure 1(e)) showed similar results compared to IL-
7/IL-15 with a signiﬁcant four-fold increase of spot numbers
(P = .021) after recall with NS3 protein. This is consistent
with observations made by Yonkers et al. and Ott et al.
showing that HCV-speciﬁc T cells remain responsive to
CD28 stimulation during chronic infection [11, 13]. This
consistency of results despite signiﬁcantly diﬀerent patient
age distributions in the aforementioned studies also shows
that patient age does not seem to inﬂuence the eﬀects of in
vitro costimulation.
3.3. Invitrocostimulationhasnoeffecton
antigen-speciﬁcTcellresponsesin
HIV-infectedpatients
In order to explore whether the aforementioned types of
costimulation have a similar eﬀect in the case of HIV
infection, we tested recall responses to three diﬀerent HIV
peptide pools in 10 HIV-infected patients. Results are shown
in Figure 2.
Unlike in HCV, some of the patients showed positive
baseline responses to HIV peptides (Figure 2(a)). How-
ever, none of the costimulatory reagents could signiﬁcantly4 Clinical and Developmental Immunology
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Figure 1: Increased responses to NS3 protein in HCV-infected patients only after in vitro costimulation with IL-7/IL-15 or anti-CD28.
PBMCs of 10 HCV-infected patients were tested in IFN-γ ELISPOT assays for their recall responses to NS3 protein and Pepset 4 peptide
pool in the absence (a) or presence of IL-7/IL-15 (b), IFN-α (c), anti-ICOS (d), or CD28 (e). For each individual, the mean spot count of
duplicate wells is shown. Horizontal bars indicate the means of all individual responses to the respective antigens. P values are given for
means that are signiﬁcantly diﬀerent from baseline values in (a). Symbols in (a) also apply to (b)–(e).Stefanie Kuerten et al. 5
enhance the overall response pattern, as shown in Fig-
ures 2(b)–2(e). None of the mean responses to any of
the antigens was signiﬁcantly elevated, regardless of the
(interindividually highly variable) baseline reactivity. Results
were also identical in both antiretrovirally treated and
untreated patients, showing that antiretroviral therapy did
not seem to inﬂuence the eﬀects of in vitro costimulation.
This decreased responsiveness of HIV-infected lymphocytes
to costimulation has previously been described by Borthwick
et al. [20] and Trimble et al. [21], and is attributed to the
downregulation of costimulatory molecules such as CD28
on T cells in the course of chronic HIV infection [22–24].
The precise mechanisms of this defect, however, are still not
understood. Our data indicate that this eﬀect may not be
limited to CD28.
3.4. Invitrocostimulationcausesfalse-positive
TcellresponsestoHCVandHIVantigensin
healthyindividuals
To date, there are no conclusive data available regarding the
eﬀect of in vitro costimulation on HCV- and HIV-speciﬁc
recall responses in healthy individuals. This information is
crucial, though, in order to be able to properly interpret
positive test results obtained from assays using in vitro
costimulation. Therefore, we speciﬁcally tested the same
HCV and HIV antigens as above in 6 healthy individu-
als (Figure 3). If in vitro costimulation enhances existing
responses without altering disease speciﬁcity, it should not
induce positive responses in healthy individuals.
As shown in Figure 3, all four methods of in vitro
costimulation (Figures 3(b)–3(e)) caused marked responses
to HCV and/or HIV antigens in several healthy individuals.
IL-7/IL-15 (Figure 3(b)) led to a strong positive response to
Pepset 4 peptide pool (twenty-fold increase above baseline;
P = .026) as well as to HIV pool 1 (ten-fold increase above
baseline; P = .030). The mean frequency of NS3 reactive
T cells was increased six-fold. Although this shift in mean
frequency is not statistically signiﬁcant due to the broad
range of anti-NS3 responses, the changes for individual
subjects are highly signiﬁcant (P = .002 for Healthy Control
1; P = .005 for Healthy Control 2).
Similarly, IFN-α also induced false-positive responses to
NS3 (Figure 3(c)), as seen in two individuals (P = .028 for
Healthy Control 1; P = .021 for Healthy Control 2). Inter-
estingly, these individuals had also displayed susceptibility to
IL-7/IL-15 stimulation (Figure 3(b)). In vitro costimulation
with anti-ICOS agonist (Figure 3(d)) upregulated anti-NS3
responses to a lesser degree. Healthy Control 4 responded
with ∼300 spots above baseline (P < .001). Remarkably,
this individual had previously proven nonreactive to both
IL-7/IL-15 and IFN-α. The mean frequency of Pepset 4
reactive T cells increased four-fold (P = .011) upon ICOS
stimulation.
Finally, as shown in Figure 3(e), CD28 costimulation
also caused false-positive test results. Healthy Control 4
responded to NS3 approximately three-fold above baseline
(P = .006). Moreover, mean spot counts for Pepset 4 were
also increased signiﬁcantly (P = .033).
4. DISCUSSION
Eﬀorts for in vitro T cell analysis attempt to establish fre-
quenciesofantigen-reactivecellsandtheireﬀectorfunctions,
deﬁned by the release of cytokines secreted upon antigen
encounter. Tetramer staining for intracellular cytokines,
cytolytic molecules, and antigen-speciﬁc T cell receptors
(TCRs) is a technique frequently used for this purpose. It
further allows the characterization of cell surface marker
expressionbyantigen-speciﬁccells,distinguishing,forexam-
ple, between central and eﬀector memory cells or between
CD4 and CD8 cells [25].
In many cases, however, there is no true dominance of
a particular peptide antigen. This has been described in
HIV and recently also in response to vaccinia virus [26].
For this reason, immune diagnostics in infectious diseases is
shifting towards the use of peptide pools as antigens. Since
this approach is unfeasible in ﬂow cytometry, functional
test systems are commonly used for this purpose in which
antigen directly activates the T cells and the resulting
cytokine secretion is detected. Cytokines can be measured in
thecellsupernatantbyELISAordirectlyaroundthesecreting
cell using ELISPOT assays. ELISPOT assays typically are
more sensitive compared to ELISA because they are able to
detect the cytokine production of each individual cell before
the cytokine is diluted into the supernatant, degraded by
proteases, or neutralized by receptors of bystander cells. As
f a ra sc e l lf r e q u e n c i e sa r ec o n c e r n e d ,E L I S P O Te s s e n t i a l l y
provides the same information as intracellular cytokine
staining (ICS). However, the detection limit of ELISPOT
can be as low as 1/100000 cells, ten times lower than ICS
[27]. Moreover, ELISPOT measures the biologically relevant
secretion of a cytokine as opposed to its intracellular storage
detected by ICS. The intracellular presence of granzyme B
or perforin, for example, merely indicates that the cell has
encounteredantigenwithinthe past month [28].Incontrast,
the actual release of granzyme B or perforin indicates
immediate antigen recognition by a speciﬁc cell [1, 2].
All of these functional assays, however, have one major
weakness in common. They provide accurate information
on T cell frequencies and function only if all speciﬁc T cells
presentinthetestcellpopulationundergofullactivation.For
example, recognition of an antigen presented by a dendritic
cell (DC) along with strong costimulation will result in full
T cell activation. This lies in contrast with T cell activation
by B cells which are known to be cells with rather weak
costimulatory capabilities [29]. In the latter case, only a
fraction of antigen-speciﬁc T cells will be fully activated.
As a consequence, the assay will mainly detect those cells
that happen to make contact with a DC instead of a B cell
when sedimenting out of single-cell suspension onto the
bottom of the test plate. Since DCs are less abundant in
peripheral blood than B cells, the frequencies of antigen-
speciﬁc T cells will be considerably underestimated. A T
cell would acquire diﬀerent eﬀector functions depending
on the type of APC presenting the antigen, and functional
assays would be strongly inﬂuenced by the prevalent types
of APC populations in the blood. Equally, conditions that
lead to APC depletion or inactivation, such as HIV and6 Clinical and Developmental Immunology
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Figure 2: In vitro costimulation has no eﬀect on antigen-speciﬁc T cell responses in HIV-infected patients. PBMCs of 10 HIV-infected
patients were tested in IFN-γ ELISPOT assays for their recall responses to HIV peptide pools 1, 2, and 3 (as described in Section 2)i nt h e
absence (a) or presence of IL-7/IL-15 (b), IFN-α (c), anti-ICOS (d), or CD28 (e). For each individual, the mean spot count of duplicate wells
is shown. Horizontal bars indicate the means of all individual responses to the respective antigens. Symbols in (a) also apply to (b)–(e).Stefanie Kuerten et al. 7
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Figure 3: In vitro costimulation causes false-positive T cell responses to HCV and HIV antigens in healthy individuals. PBMCs of 6 healthy
individuals were tested in IFN-γ ELISPOT assays for their recall responses to NS3 protein, Pepset 4 peptide pool, and HIV peptide pools 1,
2, and 3 in the absence (a) or presence of IL-7/IL-15 (b), IFN-α (c), anti-ICOS (d), or CD28 (e). For each individual, the mean spot count
of duplicate wells is shown. Horizontal bars indicate the means of all individual responses to the respective antigens. P values are given for
means that are signiﬁcantly diﬀerent from baseline values in (a). Symbols in (a) also apply to (b)–(e).8 Clinical and Developmental Immunology
cancer,wouldleavemanyantigen-speciﬁcTcellsundetected,
due to the lack of proper stimulation. This is one of the
reasons why in chronic diseases such as HIV and HCV it has
been notoriously diﬃcult to detect antigen-speciﬁc T cells in
signiﬁcant numbers. Are T cells functionally impaired under
such conditions or is their activation hampered by limited
numbers of APC? This has not been suﬃciently studied yet.
For this reason, there have been increasing eﬀorts in the
ﬁeld to include costimulatory signals in T cell activating
cultures in order to overcome the deﬁciencies of the APC
compartment or of the T cells themselves.
A prototypic costimulatory molecule is CD28 [30], the
only B7 receptor constitutively expressed on naive T cells.
In addition to ligation of TCR and MHC antigen complex,
binding of CD28 to either B7.1 or B7.2 on the APC leads to
upregulation of autocrine IL-2 secretion by the T cell. CD28
is commonly used for signal enhancement in ﬂow cytometry.
In a previous study, we found that it can also have “signal-
enhancing” activity on recall responses to tetanus, mumps,
CMV, and EBV antigens in healthy individuals.
In the experiments reported here, we extended our
previous studies and tested the eﬀects of diﬀerent types
of in vitro costimulation on HCV- and HIV-speciﬁc recall
responses not only in HCV- and HIV-infected patients, but
also in healthy individuals. Strikingly, we found that even in
healthy donors anti-CD28 induced signiﬁcant responses to
Pepset 4 antigens in addition to a strong response to NS3 in
one donor. While in HCV patients the results were weakly
increased for NS3, in HIV patients CD28 costimulation did
not result in signal enhancement to any of the antigens
tested. Therefore, we conclude that the use of anti-CD28
agonist provides no consistent beneﬁt in either HIV or HCV
infection. In vitro costimulation with a combination of anti-
CD28 and anti-CD49d antibodies led to similar results (data
not shown).
We also tested the use of IFN-α as a costimulatory
reagent. IFN-α constitutes a “danger signal” released by cells
of the innate immune system when infected with virus or
upon TLR stimulation [31]. In our study, IFN-α caused
false-positive responses to NS3 in two of the healthy donors,
while having little to no eﬀect on responses to any of the
other antigens. In HIV patients, the antigen-speciﬁc recall
responses were even reduced in the presence of IFN-α while
inHCVpatientstheywereincreasedtoNS3proteinintwoof
the patients. These data warrant further studies and clearly
show that the use of IFN-α for in vitro costimulation can
result in false-positive responses in healthy individuals while
showing no useful eﬀect in either HCV or HIV infection.
We also tested agonistic anti-ICOS antibody as a cos-
timulatory reagent. Belonging to the CD28 family [30],
anti-ICOS showed similar eﬀects to anti-CD28. It did not
have signiﬁcant eﬀects on recall responses in HIV and
HCV patients, but caused false-positive responses to NS3 in
healthy controls.
The combination of IL-7 and IL-15 has been used in
in vitro assays to increase assay sensitivity [12]. Particularly
for CD8 memory cells, both cytokines represent growth and
diﬀerentiation factors. Strikingly, the combination of IL-
7 and IL-15 induced strong responses in healthy controls
to NS3 protein, Pepset 4, and HIV pool 1. Increased
“antigen-speciﬁc” recall responses to both NS3 and Pepset
4 were also seen in HCV patients. However, in the light of
the nonspeciﬁc stimulatory eﬀect of IL-7/IL-15 in healthy
controls, these responses cannot be interpreted as speciﬁc.
Finally, similar to IFN-α, the combination of IL-7/IL-15 led
to a marked reduction of cytokine responses to all three
HIV peptide pools in HIV patients. It is unclear why HIV-
infectedindividualsrespondsodiﬀerentlycomparedtoHCV
patients and healthy controls. Possible reasons include the
reduced T cell function and susceptibility to costimulation
as a consequence of HIV infection as previously described
for CD28 [22–24].
5. CONCLUSION
Overall, our data show that in vitro costimulation with IL-
7/IL-15, IFN-α, anti-ICOS, and anti-CD28 is no “magic
bullet” providing simple solutions for improved T cell
diagnostics. There are two criteria that a method of in
vitro costimulation has to fulﬁll in order to qualify as clin-
ically and/or scientiﬁcally useful, reliably enhancing antigen
responses in a disease-speciﬁc manner without causing false-
positive responses in healthy individuals. Our results show
that essentially none of the stimulatory molecules tested
met these criteria. There are two possible interpretations of
these results. On the one hand, insuﬃcient costimulation
may not be the limiting factor in HCV or HIV patients,
whichexplainswhyadditionalcostimulationdoesnothelpto
reveal more speciﬁc activity. The other possibility is that the
functional defects present in diseases like HIV and HCV are
too severe—either on the T cell or the antigen presentation
side—to be overcome by in vitro costimulation.
ABBREVIATIONS
AIDS: Acquired immunodeﬁciency syndrome
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